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Three papers in Cell and Nature now report that dimeric RAF is a plastic enzyme: blocking one ATP-binding
site paradoxically stimulates the kinase activity of the other protomer. This occurs only in ‘‘primed’’ cells
bearing activated RAS and WT RAF, explaining the selective efficacy of RAF inhibitors for RAF mutant cells.Cancer is an obstinate beast. RAS is one
of the most feared oncogenes, driving
close to a third of all tumors, and one of
the most difficult to target. The discovery
that RAF kinases are direct effectors of
RAS raised hopes that RAF kinase inhibi-
tion would afford an effective tool to slow
RAS-driven cancers. The subsequent
discovery of BRAF mutations in human
cancers (Davies et al., 2002) inspired a
new wave of searches for BRAF-selective
inhibitors. RAF inhibitors block prolifera-
tion of BRAF mutant cell lines in vitro
and in vivo but are surprisingly ineffective
against RAS mutant cells and do not
block ERK activation in such cells (Hatzi-
vassiliou et al., 2010; Heidorn et al.,
2010; Poulikakos et al., 2010). Paradoxi-
cally, structurally-diverse ATP-competi-
tive RAF kinase inhibitors can cause acti-
vation of the RAF-MEK-ERK pathway.
This paradoxical activation of RAF by a
RAF kinase inhibitor was documented
long ago (Hall-Jackson et al., 1999) and
proposed to result from inhibitor-medi-
ated inactivation of negative feedback
loops. Three recent publications now offer
newmechanistic explanations for the RAF
inhibitor paradox (Hatzivassiliou et al.,
2010; Heidorn et al., 2010; Poulikakos
et al., 2010), based on homo- and hetero-
dimerization of CRAF and BRAF and
recognition of their roles in activating
RAF kinase activity (Rajakulendran et al.,
2009).
Crystal structures of BRAF show asym-
metric dimerization (Tsai et al., 2008; Wan
et al., 2004), and mutations that stabilize
this asymmetric ‘‘side-to-side’’ dimer are
growth-stimulatory whereas mutations
that destabilize it counteract anoncogenic
mutation (Hatzivassiliou et al., 2010;Heidorn et al., 2010; Rajakulendran et al.,
2009). Thus, alterations in RAF dimeriza-
tion or its consequences can influence
RAF signaling (Figure 1).
The new studies found that paradoxical
RAF pathway activation by RAF inhibitors
requires RAF binding to activated RAS,
but only when RAF activation is depen-
dent on RAS. Mutations disrupting RAF/
RAS binding (Heidorn et al., 2010) or
expression of dominant-negative RAS
(Hatzivassiliou et al., 2010) abrogated
paradoxical activation. However, an
N-terminally truncated and RAS activa-
tion-independent CRAF mutant was hy-
persensitive to inhibitor-mediated ERK
activation (Poulikakos et al., 2010). These
critical findings suggest that the RAF
inhibitor paradox is relevant only in a
‘‘primed’’ or pathological state. Collec-
tively, these results may both explain the
finding that RAF inhibitors are generally
well tolerated and also potentially argue
against the use of RAF inhibitors in RAS
mutant tumors.
While all three studies showed that RAF
inhibitors can activate the RAF-MEK-ERK
pathway in the context of oncogenic RAS
and that activation of CRAF is required,
the proposed mechanisms are provoca-
tively different. Heidorn et al. suggest
that selective inactivation of BRAF is crit-
ical, basing this in part on data showing
that low doses of BRAF-selective inhibi-
tors PLX4720 and 885-A enhanced ERK
activation in the presence of mutationally
active NRAS, whereas pan-RAF inhibitor
sorafenib did so only if putatively pre-
vented from binding to CRAF by introduc-
tion into CRAF of the T421N gatekeeper
mutation. In contrast, Hatzivassiliou et al.
and Poulikakos et al. argue that bindingCancer Cell 1to BRAF is not necessarily required.
Indeed, knockdown experiments showed
that MEK activation requires CRAF,
whereas knockdown of BRAF did not di-
minish compound-dependent activation.
Poulikakos et al. also found an inverse
correlation between induction of ERK
activation and the dose of six chemically
distinct ATP-competitive RAF inhibitors,
including sorafenib. They suggested that
higher doses are required to shut down
CRAF-mediated signaling, whereas lower
doses might induce ERK activation by
poorly blocking CRAF, regardless of RAF
isoform specificity. Further mechanistic
studies will be required to resolve these
discrepancies.
Direct comparisons among these
studies are difficult given their different
drugs, doses, endpoints, and cells. Con-
flicting results have emerged regarding
the roles of inhibitor off-rates, RAF mem-
brane targeting, stabilization/destabiliza-
tion of RAF heterodimer formation, re-
quirements for RAS interaction, and the
interplay between them. There may also
be several means to achieve the same
end. For example, PLX4720 (whose clin-
ical analog is PLX4032 [Garber, 2009])
has a distinct manner of interaction with
the BRAF-CRAF heterodimer and conse-
quence for RAF translocation compared
to 885-A or GDC-0879, yet all these inhib-
itors induced paradoxical activation of
MEK.
A central mystery is how ATP-competi-
tive inhibitors can bind to the catalytic
binding pocket in place of ATP and yet
activate RAF kinase activity. Poulikakos
et al. elegantly addressed this issue and
showed that inhibitor binding to kinase-
dead CRAF transactivates its dimerized7, March 16, 2010 ª2010 Elsevier Inc. 221
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Figure 1. Cell Context-Dependent Consequences of Raf Inhibitor Treatment
(A) In BRAF wild-type tumors where RAS is inactive (top left panel), tumor cell growth is not dependent on
RAF-MEK-ERK and, hence, is insensitive to RAF inhibitors. In BRAFmutant cells (top right panel), RAF inhib-
itors, particularly thosewithBRAFselectivity, potently blockmutant BRAFactivity.WithoutRASactivation, no
transactivation of CRAF occurs. In untreated RAS mutant/activated tumor cells, RAS recruits CRAF, but not
BRAF, to the plasma membrane, leading to CRAF activation of MEK and ERK (bottom panel). This model
predicts that Ras activation bymutation or upstream signaling canbe amechanismofRaf inhibitor resistance
in BRAFmutant tumor cells. Under treatment conditionswith a RAF inhibitor where only partial inactivation of
CRAF is achieved, CRAFactivationofMEK is enhancedbyRAS-GTP-dependentmembrane recruitment and
homo- or heterodimer formation with inhibitor-free CRAF. Treatment with a RAF inhibitor that fully blocks all
RAF functions would prevent transactivation, resulting in effective ERK inhibition.
(B) A criticalmolecular interaction required for inhibitor-mediated transactivation ofCRAF is the dimeric struc-
ture ofRAF. Shownhere is the structure of the three-dimensional asymmetric dimer ofBRAF (generatedbyG.
BollagandC. Zhangusing previously published coordinates [Tsai et al., 2008]). One protomer (yellow) is in the
DFG-in conformation and the other (blue) is in the DFG-out conformation. The surface outline of the DFG-out
protomer is shown lightly shaded, in part to indicate the dimeric interface. R509 from each protomer is also
highlighted to reflect its importance inanchoring thedimer. F595 from theDFGmotif is alsohighlighted to rein-
force the significant differences in the conformations of the protomers.
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Previewspartner, a kinase-competent CRAF that
cannot bind RAF inhibitor. Perhaps in
normal cells, in an energy-rich environ-
ment primed for proliferation, elevated
RAS-GTP levels induce cooperative
binding of ATP to RAF. In cancer cells,
this process might be exploited for prolif-
erative advantage.
These findings have important implica-
tions for designing next-generation RAF
inhibitors. Regardless of mechanism, all
three studies suggest that blocking CRAF
is important to avoid activating ERK sig-
naling in RAS mutant cells. An inhibitor
that does not induce RAF dimerization or
transactivation, or that inhibits both dimer-
ization partners simultaneously, would
preclude theparadoxical activation.Coad-
ministration of BRAF and MEK inhibitors
may prevent pathway activation.
What are the ramifications for using
existing RAF inhibitors in the clinic? If
decisions are based simply on the ability
to impair MEK-ERK activation, then RAF
inhibitors should be applied to BRAF,
but not RAS mutant cancers. However,
previous studies have found that MEK
inhibitor blockade of ERK activation did
not correlate with inhibition of either
anchorage-dependent or -independent
growth (Solit et al., 2006; Yeh et al.,
2009) and, thus, phospho-ERK may not
be the most predictive endpoint for anti-
tumor efficacy. However, Heidorn et al.
also explored a possible basis for the
clinically relevant finding that, while
kinase-activating BRAF mutations (e.g.,
V600E) and activating NRAS mutations
(e.g., G12D) are found in a mutually exclu-
sive manner in human cancers, kinase-
inactive BRAF mutants are also found in
human tumors and sometimes in associa-
tion with mutant RAS. Using a transgenic
mouse model of melanoma in which
both mutant KRAS (G12D) and active
RAF are required for malignancy, they
demonstrated that catalytically inactivat-
ing mutations such as D594A, presum-
ably mimicking the effects of BRAF kinase
inhibitors, can allow BRAF to become
more transforming in collaboration with
mutant KRAS. These results provide
another cautionary note for the use of
BRAF inhibitors in cancers with mutant
RAS.
Many questions remain.What is the real
RAF isoform selectivity of ‘‘BRAF-selec-
tive’’ inhibitors? Are MEK inhibitors
better? What about non-RAF effectors of
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PreviewsRas? The relative lack of toxicity seen with
RAF inhibitors argues that these remain
very much worth pursuing and worth
determining if there are conditions allow-
ing treatment of tumors with mutant
RAS. Additional, rigorous determinations
should be done in appropriate genetically
engineered mouse models of cancer to
more accurately predict patient re-
sponses. Until more decisive information
is obtained, patients enrolled in ongoing
clinical trials should be selected on the
basis of a confirmed BRAF mutation in
their tumors. Also, the risk of skin lesions
if BRAF inhibition acts as a tumor pro-
moter when oncogenic RAS is present
(Heidorn et al., 2010) indicates the impor-
tance of careful dermatological moni-
toring. Plasticity of the RAF pathway
may contribute to BRAF inhibitor resis-
tance. Finally, for patients treated with
drugs targeted to these and other path-
ways, it will be crucial to collect additionaldata to better evaluate the complex inter-
relationships of these signaling events
that together determine the success or
failure of such novel and promising thera-
peutics.
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